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Systemic delivery of self-complementary (sc) adeno-associated-virus vector of serotype
9 (AAV9) was recently shown to provide robust and widespread gene transfer to the
central nervous system (CNS), opening new avenues for practical, and non-invasive gene
therapy of neurological diseases. More recently, AAV of serotype rh10 (AAVrh10) was
also found highly efficient to mediate CNS transduction after intravenous administration in
mice. However, only a few studies compared AAV9 and AAVrh10 efficiencies, particularly
in the spinal cord. In this study, we compared the transduction capabilities of AAV9 and
AAVrh10 in the brain, the spinal cord, and the peripheral nervous system (PNS) after
intravenous delivery in neonatal mice. As reported in previous studies, AAVrh10 achieved
either similar or higher transduction than AAV9 in all the examined brain regions. The
superiority of AAVrh10 over AAV9 appeared statistically significant only in the medulla
and the cerebellum, but a clear trend was also observed in other structures like the
hippocampus or the cortex. In contrast to previous studies, we found that AAVrh10
was more efficient than AAV9 for transduction of the dorsal spinal cord and the lower
motor neurons (MNs). However, differences between the two serotypes appeared mainly
significant at low dose, and surprisingly, increasing the dose did not improve AAVrh10
distribution in the spinal cord, in contrary to AAV9. Similar dose-related differences
between transduction efficiency of the two serotypes were also observed in the sciatic
nerve. These findings suggest differences in the transduction mechanisms of these two
serotypes, which both hold great promise for gene therapy of neurological diseases.
Keywords: adeno-associated virus, AAV9, AAVrh10, gene therapy, central nervous system, peripheral nervous
system, motor neuron, SMA
Introduction
Nervous system diseases, including functional and degenerative disorders, can affect all cell types
in the central (CNS) and peripheral (PNS) nervous system, leading to severe disabilities and patient
death in the most severe cases. Due to their devastating consequences, lack of efficient treatments,
and aging of the population, these pathologies are becoming a major concern for public health.
Advances in molecular technologies have allowed emergence and rapid progress of gene therapy
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for high and sustained expression of therapeutic proteins in
nervous cells. Particular effort has been focused on vector
expression and delivery systems, those derived from the adeno-
associated virus (AAV) appearing as one of the most promising
for gene therapy of nervous diseases (Weinberg et al., 2013).
AAV vectors are non-pathogenic and capable of transducing
non-dividing cells permanently, with no toxicity or significant
immune reaction (McCown et al., 1996; Wu et al., 1998). A
number of Phase I and Phase II clinical trials utilizing AAV
vectors have been carried out worldwide (Grieger and Samulski,
2012), and among them, direct injection into the nervous
parenchyma of patients with neurological diseases has shown its
efficacy and excellent safety profile in several previous clinical
trials (Mandel and Burger, 2004; Kaplitt et al., 2007; Marks
et al., 2008; Christine et al., 2009; LeWitt et al., 2011; Tardieu
et al., 2014). However, due to the impermeability nature of the
blood-brain-barrier (BBB), systemic gene transfer to the CNS
has been particularly challenging, whether with AAV or any
other gene vector. A significant breakthrough has been made
in 2007, with our discovery that self-complementary serotype
9 AAV vectors (scAAV9) are capable to achieve widespread
gene transfer to the CNS after systemic delivery (Barkats,
2007). Although transgene expression has been firstly reported
to be primarily restricted to astrocytes after intravenous (IV)
injection in adult mice (Foust et al., 2009), we showed that
systemic delivery of an AAV9 encoding the green-fluorescent-
protein (GFP) mediated efficient transduction of a relatively large
proportion of neurons in adult mice (Duqué et al., 2009). The
comparison of single-stranded and self-complementary AAV of
serotype 1 and 9 for transduction of the mouse CNS after IV
delivery showed indeed that self-complementary AAV9 was the
most efficient vector for transducing spinal cord cells including
motor neurons (MNs), and that transgene expression lasted
at least 5 months (the duration of the study) (Duqué et al.,
2009). Importantly, this finding was successfully translated to a
domestic cat strain with deletions of the LIX1 gene (Fyfe et al.,
2006), a model of autosomal recessive spinal muscular atrophy
(SMA) similar to human type III SMA (Duqué et al., 2009). The
remarkable potential of systemic AAV9 for transducing MNs in
adult animals was further confirmed in both rodents and large
animals including non-human primates (NHPs) (Bevan et al.,
2011; Gray et al., 2011). In addition to these IV studies, we
recently reported that intramuscular (IM) delivery of AAV9 was
also effective to achieve widespread gene transfer to the CNS
in both neonatal and adult mice. Indeed, AAV9 delivery into
the gastrocnemius muscle mediated gene transfer not only into
the lumbar MNs, but also at the upper levels of the spinal cord
and in discrete parts of the brain (Benkhelifa-Ziyyat et al., 2013).
Importantly, either IV or IMdelivery of AAV9 vectors engineered
to overexpress the Survival of Motor Neuron gene 1 (SMN1)
gene dramatically rescued the pathological phenotype in a mouse
model of spinal muscular atrophy (SMA) (Foust et al., 2010;
Valori et al., 2010; Dominguez et al., 2011; Benkhelifa-Ziyyat
et al., 2013). In particular, we found that a single IV delivery of
an optimized SMN1-encoding AAV9 vector (AAV9-SMN1opti)
in neonatal SMN17 mice, a mouse model of human SMA (Le
et al., 2005), increased life expectancy up to 355 days in mice
that normally survive about 13 days (Dominguez et al., 2011).
The AAV9-SMN1opti treatment also partially corrected the body
weight loss phenotype, improved motor activity, and prevented
MN degeneration (Dominguez et al., 2011). Systemic AAV9
delivery was further shown to be very promising for treating
other neurological or lysosomal diseases, including amyotrophic
lateral sclerosis (Yamashita et al., 2013), Canavan disease (Ahmed
et al., 2013) or MPSIIIA (Fu et al., 2011; Ruzo et al., 2012),
highlighting the outstanding potential of this approach for a large
range of CNS and systemic pathologies.
Although AAV9 is usually considered as the most promising
vector for achieving widespread CNS transduction, alternative
AAV vectors with increased spread and transduction efficiency
are currently actively investigated. In particular, the AAV of
serotype rh10 (AAVrh10), which has been isolated from rhesus
monkeys (Gao et al., 2002, 2003), was recently reported to be
as least as efficient as AAV9 for transduction of many tissues
including the CNS in neonatal mice (Hu et al., 2010; Zhang et al.,
2011). In particular, using a scoring system to evaluate GFP-
immunoreactivity in different CNS regions, Zhang et al. showed
that AAVrh10 transduction efficiency was comparable to that
of AAV9 in the spinal cord, and was globally higher than that
of AAV9 in the brain (with differences according to the brain
region) (Zhang et al., 2011).
In this study, we used semi-quantitative and quantitative
analyses to compare the ability of AAV9 and AAVrh10 for
achieving gene transfer to the CNS and the PNS following
intravascular delivery in neonatal mice. We found that low
dose AAVrh10 induced higher transduction than AAV9 of
most regions that we examined, in particular the medulla, the
cerebellum, the spinal cord and the sciatic nerve. However,
differences between the two serotypes were less evident were
the vector doses were increased, suggesting serotype-related
differences in the transduction process.
Materials and Methods
Animals
Wild-type animals were obtained from Smn1+/−,
Smn2+/+ breeding (FVB.Cg-Tg(SMN2)89Ahmb Tg
(SMN1∗A2G)2023Ahmb Smn1 tm1Msd/J) (number 5024,
Jackson Laboratories, Main Harbor, USA). Mice were housed
under controlled conditions (22 ± 2◦C, 50 ± 10% relative
humidity, 12 h/12 h light/dark cycle, food, and water ad libitum).
All animal experiments were carried out in accordance with
European guidelines for the care and use of experimental animals
and approved by the Charles Darwin N◦5 Ethics Committee on
Animal Experiments (agreement n◦01883.02-16/9/14).
Production of AAV Vectors and Intravenous
Delivery
AAV vectors of serotype 9 or rh10, carrying the GFP under
the control of the cytomegalovirus immediate/early (CMV)
promoter were prepared by the triple transfection method in
HEK293T cells, as previously described (Duqué et al., 2009).
Briefly, cells were transfected with (i) the adenovirus helper
plasmid, (ii) the AAV packaging plasmid encoding the rep2
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and cap9 (p5E18-VD2/9) or cap-rh10 genes, and (iii) the
AAV2 plasmid expressing CMV-GFP. Seventy-two hours after
transfection, cells were harvested, frozen/thawed four times, and
AAV vectors were purified by ultracentrifugation through an
iodixanol gradient (Sigma-Aldrich, St Quentin Fallavier, France)
and concentrated with Amicon Ultra–Ultra cell 100K filter units
(Millipore) in PBSMK buffer (0.1M phosphate buffered saline
solution (PBS), 1mM MgCl2 and 2.5mM KCl). Aliquots were
stored at −80◦C until use. Vector titers were determined by
real-time PCR and expressed as viral genomes per mL (vg/mL).
Neonatal mice (P0) received 40µL of viral suspension
containing 3× 1010 or 1× 1011 vg of AAV9 or AAVrh10 into the
temporal vein using an Hamilton syringe with a 32-gauge needle
(Hamilton).
Western Blot
Animals were lethally anesthetized and transcardially perfused
with 0.1M PBS. Tissues were immediately frozen in liquid
nitrogen and stored at −80◦C until use. For protein extraction,
tissues were grinded in a lysis buffer (150mM NaCl, 50mM
Tris–HCl, 0.5% sodium deoxycholate, 1% NP40, 1% SDS)
supplied with protease inhibitors cocktail (CompleteMini, Roche
Diagnostics). Lysates were quantified with the DC protein assay
(BioRad,) and 50µg were loaded on a 10% polyacrylamide gel
(Criterion XT 10% bis-Tris, Biorad). Proteins were transferred
onto a PVDF membrane (Imobilon P, Millipore). Successively,
membranes were blocked with a Tris-buffered saline solution
(10mM Tris–HCl pH 7.4, 150mM NaCl) and 0.05% Tween
20 (TBS-T) containing 5% fat-free dry milk. Membranes were
incubated overnight at 4◦C with a rabbit anti-GFP antibody
(1:10,000; Abcam) or a mouse anti-α-tubulin antibody (1:10,000;
Sigma-Aldrich) diluted in TBS-T, 5% fat-free dry milk. After
washes in TBS-T buffer, membranes were incubated with
horseradish peroxidase conjugated anti-mouse or anti-rabbit
secondary antibodies (1:10,000, Amersham Pharmacia Biotech)
for 1 h at room temperature. Western blots were developed using
SuperSignal West Dura kit (Thermoscientific).
Immunofluorescence
Animals were lethally anesthetized and transcardially perfused
with 0.1M PBS followed by 4% paraformaldehyde (PFA; Sigma-
Aldrich) in PBS. Tissues were harvested and successively
incubated in 4% PFA (24 h at 4◦C) and in a PBS-sucrose solution
(30% sucrose for the spinal cord, 15% sucrose for the other
organs, overnight at 4◦C). Samples were imbedded with optimal
cutting temperature medium (Tissue-Tek OCT; Sakura Finetek)
and frozen in cold isopentane. Fourteen µm-thick sections
were serially cut on a cryostat (Leica Microsystems) and stored
at−80◦C.
For immunofluorescence staining, sections were incubated
in a blocking solution containing 4% donkey serum, 5%
Bovine serum albumin in a PBS-triton X-100 buffer (0.1M
PBS, 0.4 % Triton X-100) for 1 h at room temperature.
Sections were incubated with primary antibodies: anti-GFP
(1:2,000, rabbit; Abcam), anti-Neurofilament (NF, mouse, 1:500;
Millipore), anti-β-S100 (rabbit, 1:200; Dako) or anti-Choline
Acetyltransferase (ChAT, goat, 1:100, Millipore), in the blocking
solution, overnight at 4◦C. After PBS washings, sections were
incubated with secondary antibodies conjugated with Alexa
Fluor 488 (1:500) or 594 (1:300) (Molecular Probes-Invitrogen).
Nuclei were counterstained with 4′,6′-diamidino-2-phénylindole
(DAPI, 0.5µg/mL in PBS; Sigma-Aldrich) and mounted with
Fluoromount (Southern Biotech). Pictures were obtained with
a confocal laser scanning microscope (Leica) or a motorized
fluorescence microscope (AxioImager.Z1; Zeiss).
To quantify GFP expression, representative images from each
tissue were taken at identical camera and microscope settings
with a fluorescence microscope. For every image, the brightness
and background values were measured with ImageJ software
(Rasband 1997–2006; National Institutes of Health, Bethesda,
MD, http://rsb.info.nih.gov/ij/), and the results corresponded to
the mean value of 6 (brain andmedulla) or 12 (cerebellum, dorsal
spinal cord, sciatic nerve, DRG, heart, and liver) images for each
mouse.
Statistics
All data were analyzed using Prism software (version 4.0,
GraphPad). A Mann-Whitney test was used for the analysis
of western blot results, t-test and One-Way ANOVA were
performed for analysis of MN counting. Fluorescence imaging
data were treated with either a Mann-Whitney or a Two-Way
ANOVA test, which were chosen according to the number of
samples. Significant levels were noted as follows: ∗, p < 0.05; ∗∗,
p < 0.01; ∗∗∗, p < 0.001.
Results
Intravenous AAVrh10 Provides a Similar or Higher
Brain Transduction Level than AAV9
Newborn mice were injected at P0 into the superficial temporal
vein with the AAV9-GFP (n = 4) or AAVrh10-GFP (n = 4)
vectors (3 × 1013 vg/kg), and transduction efficiency was first
compared in the brain by immunofluorescence analysis 1 month
after injection. For both vectors, a gradient of expression
was observed from the brain ventricles and adjacent regions
(Bregma −1.46 and −6.48mm), to more distant brain regions
(Figure 1). GFP immunostaining was particularly intense in the
choroid plexus of the lateral, 3rd and 4th ventricles, and in
neighboring structures such as the lateral habenular nucleus,
the CA2 field of the hippocampus, the dorsal hippocampal
commissure, the deeper layers of the cerebral cortex, the
retrosplenial cortex, the vestibular nucleus and the spinal
trigeminal nucleus of the medulla, and the lobule 10 of the
cerebellum (Figure 1). In contrast, only a few GFP-expressing
cells were observed in regions located far from the ventricles,
such as the reticular nucleus, the thalamus or the external
lobules of the cerebellum. In all the examined regions, a similar
or higher level of transduction was observed with AAVrh10
compared to AAV9, AAVrh10 providing the greatest levels of
expression in the cerebellar Purkinje cells, the vestibular and
spinal trigeminal nuclei of the medulla, the lateral habenular
nucleus, and the deep cortical layers (Figure 1). A quantitative
analysis of the GFP signal (mean intensity/pixel) in several
brain structures confirmed a strong tendency for a superior
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FIGURE 1 | Immunofluorescence analysis of GFP expression in the
brain of AAV9 or AAVrh10 injected mice. Representative brain
sections treated for GFP immunofluorescence 30 days after injection of
GFP-expressing AAV9 and AAVrh10 vectors into the facial vein of
neonatal mice at P0 (3× 1013 vg/kg, n = 4 per group) (A) Schematic
representation of the investigated areas (B,C, Bregma: −1.46mm; D–I,
Bregma: −6.48mm). (B–I) Comparison of GFP expression in AAV9-GFP
(B,D,F,H) or AAVrh10-GFP (C,E,G,I) injected mice in (B,C) the
hippocampus (D,E) the medulla (F,G) the spinal trigeminal tractus and
nucleus, and (H,I) the cerebellum. 3V, third Ventricle; 4V, fourth Ventricle;
DG, Dentate Gyrus; dhc, dorsal hippocampal commissure; Gi,
Gigantocellular reticular nucleus; GL, Granular layer; LHb, Lateral
Habenular nucleus; ML, Molecular layer; PL, Purkinje layer; RS,
Retrosplenial cortex; sp5, Spinal trigeminal tractus; sp, Spinal trigeminal
nucleus; T, Thalamus; Ve, Vestibular nucleus. Scale bars = (B–E)
250µm; (F–I) 125µm.
transduction efficiency of the AAVrh10, however the difference
with AAV9 only reached statistical significance for the medulla
(30.9 ± 8 vs. 74.2 ± 12.9 for AAV9 and AAVrh10, respectively;
p = 0.0286) and the cerebellum (11.7 ± 1.7 vs. 38.5 ±
6.1 for AAV9 and AAVrh10, respectively; p = 0.0286)
(Figure 2).
GFP Expression in the Spinal Cord of AAV9 and
AAVrh10 Injected Mice
To compare transduction levels provided by the AAV9 and
AAVrh10 serotypes in the spinal cord, neonatal mice were
injected at birth with the two GFP-expressing vectors. Both
vectors were delivered at low (3×1013 vg/kg, n = 6 per AAV) and
high dose (1014 vg/kg, n = 4 for AAV9 and n = 3 for AAVrh10)
and GFP expression was evaluated 30 days after injection by
western blot analysis on spinal cord protein extracts.
Similarly to the results in brain, GFP protein levels were
found to be increased in spinal cord extracts from mice
injected with AAVrh10 compared to AAV9 at 3 × 1013 vg/kg
(p = 0.011) (Figure 3). At this low dose, only a weak
GFP expression was observed with both vectors, which was
essentially confined to the dorsal part of the spinal cord
(corresponding to the sensitive nerves of the fasciculus gracilis
and cuneatus) (Figure 3Ba). At the highest dose (1014 vg/kg),
GFP expression levels were largely increased in the spinal cord,
but no statistically significant difference was evidenced between
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FIGURE 2 | Quantification of GFP fluorescence intensity in the brain of
AAV9 or AAVrh10 injected mice. Average GFP signal intensity/pixel was
measured 30 days after intravenous delivery of AAV9-GFP or AAVrh10-GFP
(3× 1013 vg/kg, n = 4 for each vector) in neonatal mice. (A) Motor cortex (B)
retrosplenial cortex (C) hippocampal region (D) dentate gyrus (E) lateral
habenular nucleus (F) thalamus (G) medulla (H) cerebellum. The data
represent the mean values ± SEM of GFP fluorescence intensity/pixel
(Mann-Withney test; *p < 0.05).
the two vectors (Figure 3). Quantitative analysis of the intensity
of GFP immunofluorescence in the dorsal spinal cord columns
confirmed the superiority of AAVrh10 vs. AAV9 in this region at
low dose (p = 0.0157) (Figure 3C).
As illustrated in Figure 4, GFP expression was also detected in
the ventral horn of the spinal cord, from the cervical to lumbar
levels (Figure 4A). MN transduction efficiency mediated by
AAV9 and AAVrh10 was compared by co-immunofluorescence
analysis using GFP and Choline Acetyltransferase (ChAT), a MN
marker. Counting of GFP-positive ChAT MNs revealed that the
mean percentage of transduced MNs was doubled throughout
the spinal cord from mice injected with AAVrh10 compared
to AAV9 at low dose (Figures 4Ba,Bb). Indeed, 22.1, 12.9,
and 12.8% of MNs were transduced in the cervical, thoracic,
and lumbar spinal cord after injection of low dose AAVrh10,
vs. 11.8, 6.16, and 7.26% with AAV9 (p = 0.0001, 0.0403,
and 0.0318) (Figures 4Ba,Bb). The superiority of AAVrh10
over AAV9 was less striking at the highest dose but was still
significant in the whole spinal cord (Figure 4Bc). However, MN
transduction analysis in each spinal cord segment showed a
statistically significant difference only at the cervical level (25.9
vs. 20.2% for AAVrh10 and AAV9, respectively; p = 0.0049)
(Figure 4Bd).
Comparison of AAV9 and AAVrh10-mediated
Transduction of the Peripheral Nervous System
We further compared transgene expression provided by the
two AAV serotypes in the PNS, in particular the dorsal
root ganglia (DRG) and the sciatic nerve. In the DRG,
no significant difference was observed between AAV9 and
AAVrh10 injected animals, although a strong tendency for an
increased GFP immunofluorescence intensity was noted with
AAVrh10 compared to AAV9 at the low dose (Figures 5A,C).
Similarly, a difference between the two vectors was observed
for transduction of the sciatic nerve only at the low dose
(p = 0.02) (Figures 5B,D). At high dose, the intensity of GFP
immunofluorescence was markedly increased, in particular with
AAV9, with no significant difference between the two serotypes
(p = 0.64) (Figures 5B,D). This dose-related effect on the
transduction efficiency provided by AAV9 and AAVrh10 was
demonstrated by a statistically significant “AAV serotype by dose”
interaction (Two-Way ANOVA, p = 0.006).
To further examine the distribution of the GFP protein
in the sciatic nerve, co-immunofluorescence analyses were
performed using antibodies against neurofilament (NF), a
specific axonal marker, and β-S100, a marker for myelinating
and non-myelinating Schwann cells. Our results showed that
both AAV9 and AAVrh10 provided efficient transduction of NFs
(Figures 5Ea,Eb) and Schwann cells (Figures 5Ec,Ed), with no
obvious difference between the two serotypes. Of note, GFP was
highly expressed in the Schwann cells that surrounded the axons,
highlighting gene transfer in the myelinating subpopulation
(Figures 5Ec,Ed).
Comparison of AAVrh10 and AAV9-mediated
Heart and Liver Transduction
We finally examined two tissues, the heart and the liver,
which were previously demonstrated as differentially transduced
following intravascular injection of AAV9 or AAVrh10 (Hu
et al., 2010; Piras et al., 2013). A global high transduction
of the heart was found for both serotypes, the GFP-positive
cells appearing widely distributed in the atria and ventricles
(Supplementary Figures 1Aa–d). However, AAVrh10-mediated
transduction of the cardiomyocytes was significantly higher than
that provided by AAV9 at both low and high doses (Two-Way
ANOVA, p = 0.0051) (Supplementary Figure 1Ae). The liver
was found relatively weakly transduced, in particular at low
dose (Supplementary Figures 1Ba–d), but similarly to results
in the heart, a tendency for an increased transduction level
was found with AAVrh10, although the difference between
the two serotypes did not reach any statistical significance
(Supplementary Figure 1Be).
Discussion
A number of comparative studies have reported improved CNS
gene transfer after brain injection of AAV9 and AAVrh10, two
newly identified AAV serotypes which have been isolated from
the tissues of NHPs (rhesus or cynomolgus monkeys) (Gao et al.,
2002, 2003; Mori et al., 2004). Both vectors were found to provide
more efficient and widespread neuronal transduction in rodents
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FIGURE 3 | GFP expression in the spinal cord of AAV9-GFP or
AAVrh10-GFP injected mice. (A) Western blot and (B)
immunofluorescence analyses were performed 30 days after
intravenous injection of the vectors in neonatal mice. (A)
Western-blot and corresponding densitometric analyses of GFP
expression in whole spinal cord lysates injected with (a,b) low dose
(3× 1013 vg/kg) or (c,d) high dose (1014 vg/kg) of AAV9-GFP or
AAVrh10-GFP vectors (n = 6 for low dose AAV9 or AAVrh10, n = 4
and 3 for high dose AAV9 and AAVrh10, respectively). Controls
were protein extracts from non-injected mice and α-tubulin was
used as internal loading control. Data in (b,d) represent the mean
values ± SEM of GFP levels relative to α-tubulin levels
(Mann-Withney test; *p < 0.05). (B) Representative sections of the
cervical, thoracic and lumbar spinal cord treated for GFP
immunofluorescence after injection of AAV9 and AAVrh10 at (a) low
dose (3× 1013 vg/kg, n = 4 per vector) or (b) high dose (1014 vg/kg,
n = 4 per vector). Panels at the bottom left corner showed high
magnification indicated with a white asterisk. Scale bars = 250µm.
(C) GFP fluorescence intensity/pixel in the dorsal spinal cord of
mice (n = 4 per vector and per dose). Results are expressed as
mean of four independent experiments ± SEM (Two-Way ANOVA
test, Bonferroni Post-test: *p < 0.05).
as compared to the first characterized AAV2 serotype, or even
to other robust serotypes such as AAV8, with some variability
capabilities at spreading and transducing specific brain structures
(Cearley and Wolfe, 2006; Sondhi et al., 2007; Klein et al., 2008;
Miyake et al., 2011; Rafi et al., 2012; Hordeaux et al., 2015).
The unprecedented potential of self-complementary AAV9
for mediating widespread transgene expression in neuronal cells
after systemic injection was recently demonstrated in both adult
(Barkats, 2007; Duqué et al., 2009; Benkhelifa-Ziyyat et al.,
2013) and neonatal animals (Barkats, 2007; Duqué et al., 2009;
Foust et al., 2009; Benkhelifa-Ziyyat et al., 2013), including large
animals such as cats (Barkats, 2007; Duqué et al., 2009) and
NHPs (Bevan et al., 2011; Gray et al., 2011). This practical and
non-invasive gene therapy approach has opened the way to first
clinical trials in human, in particular for SMA type1 patients.
Interestingly, recent studies showed that AAVrh10 also provided
strong and widespread CNS transduction after intravenous
administration in mice (Hu et al., 2010; Zhang et al., 2011; Mattar
et al., 2013; Bucher et al., 2014; Hordeaux et al., 2015). In this
study, we compared the capabilities of AAV9 and AAVrh10 at
transducing different regions of the brain, the spinal cord and the
PNS after intravenous injection in neonatal mice. As previously
reported for AAV of serotypes 9 and rh10 by Cearley and Wolfe
(2006), and with other serotypes by Davidson et al. (2000),
variability was often observed between animals intravenously
injected with the same serotype. However, the trends for a
superiority of AAVrh10 transduction efficacy over AAV9 were
evident in most CNS and PNS regions that we examined, with
significant differences between the two vectors being found in the
medulla, the cerebellum, the spinal cord and the sciatic nerves.
Two main studies in neonatal mice have previously reported
a greater transduction efficiency of AAVrh10 vs. AAV9 vectors
in the brain following intravenous delivery (Hu et al., 2010;
Zhang et al., 2011). As in our study, Zhang et al. showed in
particular the superiority of AAVrh10 to transduce brain regions
such as the hippocampus, the cerebellum or the medulla (Zhang
et al., 2011). However, no difference between the two serotypes
was reported in the spinal cord, in contrast to what we have
demonstrated by western blot analysis of GFP protein levels in
the whole spinal cord, quantification of GFP intensity levels in
the dorsal spinal cord, and manual counting of the transduced
MNs in the ventral spinal cord. Interestingly, our results showed
that intravenous delivery of low dose AAVrh10 (3 × 1013 vg/kg)
in neonatal mice led to the transduction of a number of MNs
similar to that targeted with high dose AAV9 (1014 vg/kg). This
finding suggested that using AAVrh10 could present potential for
reducing the vector titer required for therapeutic translation to
patients.
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FIGURE 4 | Comparison of lower motor neuron transduction in AAV9
and AAVrh10 injected mice. (A) Representative cervical spinal cord sections
treated for GFP/ChAT co-immunostaining 30 days after intravenous injection
of neonatal mice with low (a–f) and high (g–l) doses of AAV9 or AAVrh10
vectors (a,d,g,j) GFP-positive cells (b,e,h,k) ChAT-positive MNs; (c,f,i,l) merge
(asterisks: double-stained MNs; panels at the top right corner: high
magnification). Scale bars = 50µm. (B) Percentage of GFP/ChAT-positive
MNs in the whole spinal cord (a,c) and in each spinal cord segment (b,d) at low
(a,b) and high (c,d) dose of AAV. Data are means ± SEM (n = 4) and
differences between groups were analyzed by Student t-test in (a,c) and
One-Way ANOVA, Newman-Keuls post-hoc-test in (b,d); *p < 0.05;
**p < 0.01; ***p < 0.001.
Of note, the superiority of AAVrh10 over AAV9 for MN
transduction was mainly observed at low dose, the difference
between the two vectors administered at high dose being only
significant in the cervical spinal cord. Indeed, the increase of
the vector titer induced a rise in AAV9 transduction efficiency,
without further significant augmentation of that of AAVrh10.
This finding is in accordance with the assumption that more
AAVrh10 than AAV9 particles could transduce a single cell,
without transducing an increased number of cells, as previously
suggested in the comparative study of several AAV serotypes
injected into the mouse brain (Cearley and Wolfe, 2006), and
more recently, after infusion of the serotypes into the striatum
FIGURE 5 | GFP expression in the dorsal root ganglia and sciatic nerve
of AAV9-GFP and AAVrh10-GFP injected mice. (A,B) Representative
sections of (A) dorsal root ganglia and (B) sciatic nerve, treated for GFP
immunofluorescence 30 days after neonatal delivery of AAV9 or AAVrh10 at
low (a,b) and high (c,d) dose (n = 4 per dose and per serotype) (C,D)
Quantification of GFP intensity/pixel in the dorsal root ganglia (C) and sciatic
nerve (D) sections. Results are expressed as mean ± SEM (n = 4; Two-Way
ANOVA analysis, Bonferroni Post-hoc-test: ***p < 0.001). (E) Representative
sciatic nerve sections treated for (a,b) GFP/NF co-immunostaining (green:
GFP; red: NF; yellow: merge) or (c,d) GFP/β-S100 co-immunostaining (green:
GFP; red: β-S100; yellow: merge), 30 days after intravenous injection of
neonatal mice with AAV9 (a,c) or AAVrh10 (b,d) at high dose (1014 vg/kg).
Scale bars = (A) 50µm; (B) 100µm; (C) 20µm.
of rats and pigs using convection-enhanced delivery (White
et al., 2011). In the latter study, no greater distribution was
induced by increasing the infusion titer of AAVrh10, in contrast
to AAV9 whose distribution continued to rise (White et al.,
2011). Likewise, we found the sciatic nerve to be preferentially
transduced by AAVrh10, but only at low dose. Increasing
the vector titer induced a marked increase of GFP intensity
levels in whole sciatic nerve sections from AAV9 injected
mice, without further rise when mice were injected with high
dose AAVrh10, corroborating the results obtained in the spinal
cord. Together, these results and those of the literature suggest
that the superior transduction efficacy of AAVrh10 would be
related to a greatest amount of particles entering nervous cells,
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rather than to a particular wide distribution of its receptors.
Of note, the superiority of systemic AAVrh10 over AAV9
could also be dependent of genome conformation, since a
study of Miyake et al., comparing several single-stranded AAVs
(ssAAVs) intravenously delivered in neonatal mice, reported that
transduction efficiencies of all vectors including ssAAVrh10 were
low as compared to ssAAV9 (Miyake et al., 2011).
Differences between the serotype 9 and rh10 for CNS
transduction efficiency could also be due to differential
capabilities for entering nervous tissue following systemic
delivery. Pathways by which AAV9 or AAVrh10 could enter
the CNS could include transmigration or receptor mediated
transcytosis across the endothelium of blood-brain barrier (BBB)
and/or across the blood-cerebral spinal fluid barrier (blood-CSF
barrier) at the choroid plexus as previously suggested (Barkats,
2007; Duqué et al., 2009) and previously assumed for HIV
infection of the human brain (Falangola et al., 1995; Pereira
and Nottet, 2000). As HIV viruses, AAV9 or AAVrh10 could
also enter the CNS tissue at the level of the circumventricular
organs (CVO), which are brain structures devoid of BBB thereby
providing a possible site of infection (Johnson and Gross, 1993;
Davson and Segal, 1996).
In view of the difference in the extent and intensity of
transgene expression according to the brain structures, and
of the gradient which was observed from the brain ventricles
and adjacent regions to remote areas, our results are best in
support of a preferential crossing at the choroid plexus. Indeed
these structures were found to be robustly transduced in the
3rd and 4th ventricles, as well as neighboring parenchymal
areas such as the hippocampus and the cerebellum. However,
remote areas located far from the ventricles such as the cortex
or the thalamus were also efficiently targeted, suggesting that
other routes of entry into the CNS should also be taken,
such as diffusion from the CVO. However, further experiments
will be necessary for fully understanding the mechanism by
which specific AAV serotype such as AAV9 and AAVrh10
enter into the brain and the spinal cord after systemic
injection.
In addition to its high potential for CNS transduction,
AAVrh10 was suggested to be an attractive alternative serotype
to AAV9, particularly by the fact that it would be less prone to
induce host serological immune response than AAV9 (Hordeaux
et al., 2015). Indeed, humans should be less exposed to AAVrh10
since this vector is a rhesus monkey serotype, unlike the human
AAV9 serotype. However, a recent study surprisingly reported
a 59% IgG prevalence against AAVrh10 in humans, and 47%
against AAV9 (Thwaite et al., 2015). Although most anti-
AAVrh10 IgG were non-neutralizing (as anti-AAV9 IgG) their
high prevalence in humans does not support the assumption
of a particular immunological advantage of AAVrh10 over
other serotypes. Moreover, antibody cross-recognition was also
reported in humans, suggesting that a broad repertoire of
preexisting antibodies would be able to react with non-human
serotypes (Thwaite et al., 2015).
Although many studies have reported the high efficiency of
AAVrh10 for CNS gene transfer, only a few compared AAV9
and rAAVrh10. This study suggests that, like AAV9, AAVrh10
holds promise for intravascular gene therapy of human CNS and
PNS diseases affecting neurons, astrocytes, oligodendrocytes or
Schwann cells. Our most significant finding was the superiority
of AAVrh10 over AAV9 for MN transduction in neonatal mice,
highlighting the particular potential of this serotype for SMA
type1, a devastating disease affecting young children. Several
brain regions were also reported to be affected in SMA type I
patients, including the brainstem and the cerebellum (Harding
et al., 2015), which were found highly transduced by serotype
rh10. AAVrh10-mediated restoration of SMN in these brain
areas could thus be important for gene therapy of SMA type
1. It should however be noted that the superiority of serotype
rh10 over serotype 9 was mainly observed at low dose. The fact
that AAVrh10 distribution was not improved by increasing the
vector dose, whereas a dose-dependent increase of transduction
efficiency was observed with AAV9, suggest differences in the
transduction mechanisms of these two vectors which both
present great interest for gene therapy of neurological diseases.
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